>
Five Prime Therapeutics Inc logo

FPRX - Five Prime Therapeutics Inc Share Price

$38 0.0  0.0%

Last Trade - 15/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £1.27bn
Enterprise Value £1.06bn
Revenue £9.46m
Position in Universe th / 6852
Bullish
Bearish
Unlock FPRX Revenue
Momentum
Relative Strength (%)
1m -4.88%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -2.31%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
379.8 30.7 39.5 49.9 14.9 13.2 12.2 10.00 -48.9%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, FivePrime Therapeutics Inc revenues decreased 11% to $13.2M.Net loss decreased 39% to $84.3M. Revenues reflectCollaboration decrease of 45% to $8.2M. Lower net lossreflects Research and development - Balancing val decreaseof 38% to $65.8M (expense), Stock-based Compensation in SGAdecrease of 53% to $6.9M (expense), Stock-basedCompensation in R&D decrease of 59% to $3.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for FPRX
Graphical History

Revenue

FPRX Revenue Unlock FPRX Revenue

Net Income

FPRX Net Income Unlock FPRX Revenue

Normalised EPS

FPRX Normalised EPS Unlock FPRX Revenue

PE Ratio Range

FPRX PE Ratio Range Unlock FPRX Revenue

Dividend Yield Range

FPRX Dividend Yield Range Unlock FPRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
FPRX EPS Forecasts Unlock FPRX Revenue
Profile Summary

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company’s pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 20, 2001
Public Since September 18, 2013
No. of Shareholders: 24
No. of Employees: 51
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue 46,572,029
Free Float (0.0%)
Eligible for
ISAs
SIPPs
FPRX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for FPRX
Upcoming Events for FPRX
Frequently Asked Questions for Five Prime Therapeutics Inc
What is the Five Prime Therapeutics Inc share price?

As of 15/04/21, shares in Five Prime Therapeutics Inc are trading at $38, giving the company a market capitalisation of £1.27bn. This share price information is delayed by 15 minutes.

How has the Five Prime Therapeutics Inc share price performed this year?

Shares in Five Prime Therapeutics Inc are currently trading at $38 and the price has moved by 1.25k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Five Prime Therapeutics Inc price has moved by 0.816k% over the past year.

What are the analyst and broker recommendations for Five Prime Therapeutics Inc?

Of the analysts with advisory recommendations for Five Prime Therapeutics Inc, there are there are currently 1 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Five Prime Therapeutics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Five Prime Therapeutics Inc next release its financial results?

Five Prime Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Five Prime Therapeutics Inc dividend yield?

Five Prime Therapeutics Inc does not currently pay a dividend.

Does Five Prime Therapeutics Inc pay a dividend?

Five Prime Therapeutics Inc does not currently pay a dividend.

When does Five Prime Therapeutics Inc next pay dividends?

Five Prime Therapeutics Inc does not currently pay a dividend.

How do I buy Five Prime Therapeutics Inc shares?

To buy shares in Five Prime Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Five Prime Therapeutics Inc?

Shares in Five Prime Therapeutics Inc are currently trading at $38, giving the company a market capitalisation of £1.27bn.

Where are Five Prime Therapeutics Inc shares listed? Where are Five Prime Therapeutics Inc shares listed?

Here are the trading details for Five Prime Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: FPRX
What kind of share is Five Prime Therapeutics Inc?

We were not able to load our ranking data for Five Prime Therapeutics Inc

Is there a Five Prime Therapeutics Inc share price forecast 2021?

Shares in Five Prime Therapeutics Inc are currently priced at $38. At that level they are trading at 6.58% premium to the analyst consensus target price of 0.00.

Analysts covering Five Prime Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.317 for the next financial year.

How can I tell whether the Five Prime Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Five Prime Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 0.424k%. At the current price of $38, shares in Five Prime Therapeutics Inc are trading at 0.151k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Five Prime Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Five Prime Therapeutics Inc.

Who are the key directors of Five Prime Therapeutics Inc?

We were unable to find the directors for Five Prime Therapeutics Inc.

Who are the major shareholders of Five Prime Therapeutics Inc?

Here are the top five shareholders of Five Prime Therapeutics Inc based on the size of their shareholding:

BVF Partners L.P. Hedge Fund
Percentage owned: 13.61% (6.34m shares)
RA Capital Management, LP Hedge Fund
Percentage owned: 9.2% (4.29m shares)
Rock Springs Capital Management LP Hedge Fund
Percentage owned: 6.53% (3.04m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.9% (2.75m shares)
RTW Investments L.P. Investment Advisor/Hedge Fund
Percentage owned: 5.4% (2.52m shares)
Similar to FPRX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.